Vir Biotechnology Inc's Customers Performance

Name: Vir Biotechnology Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

VIR

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


VIR's Source of Revenues		During the corresponding time, Vir Biotechnology Inc recorded a revenue increase by 19582.54 % year on year, While revenue at the Vir Biotechnology Inc 's corporate clients • List of VIR Customers

for the same period Vir Biotechnology Inc recorded revenue increase by 19582.54 % year on year,

• List of VIR Customers

Vir Biotechnology Inc's Business Units


License and Collaboration Revenue	99.98 %	of total Revenue
Reportable	99.99 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Vir Biotechnology Inc's Comment on Sales, Marketing and Customers

News about Vir Biotechnology Inc Contracts

A New Dawn in Chronic Hepatitis B Treatment Vir Biotechnologys Promising MARCH Study Results Illuminate the Path Ahead

In the evolving landscape of hepatitis B treatment, the glimmer of hope shines brighter than ever, thanks to the recent findings from Vir Biotechnology, Inc.’s MARCH Phase 2 clinical study. Based in the vibrant city of San Francisco, this groundbreaking research sheds light on the efficacy of two innovative therapeutic agents, tobevibart and elebsiran, in tackling chronic hepatitis B (CHB). As the battle against this persistent viral infection continues, the preliminary 24-week post-end of treatment data presents an exciting advancement that could transform patient outcomes and the future of hepatitis B therapy.Hepatitis B remains a significant global health threat, infecting millions and causing severe li...

Vir Biotechnology’s MARCH Study Sparks Hope for a Cure Breakthrough Results in Chronic Hepatitis B Treatment...

In a significant stride toward effective treatments for chronic hepatitis B (HBV), Vir Biotechnology, Inc. (Nasdaq: VIR) has announced promising end-of-treatment results from the MARCH Phase 2 clinical study during the recent AASLD The Liver Meeting in San Francisco. The study evaluated innovative combinations of tobevibart and elebsiran two potential therapies designed to target this persistent viral infection either alone or in tandem with pegylated interferon alfa (PEG-IFN).Chronic hepatitis B remains a global health concern affecting over 250 million individuals worldwide. The virus can lead to serious complications, including liver cirrhosis and hepatocellular carcinoma, making advancements in treatment...

VIR's Stock Performance relative to it's Customers

VIR's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Vir Biotechnology Inc	1,823.89	65.50	-442.72	367
SUBTOTAL	0.00	0.00	0.00	-

Sources: Vir Biotechnology Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Vir Biotechnology Inc’s corporate clients.
For your research, we’ve provided 9 tables on Vir Biotechnology Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.